Department of Biopharmaceutical Chemistry, Kookmin University, Seoul 02707, Korea.
Biopharmaceutical Chemistry Major, School of Applied Chemistry, Kookmin University, Seoul 02707, Korea.
Medicina (Kaunas). 2022 May 11;58(5):649. doi: 10.3390/medicina58050649.
Ovarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) and how the signaling pathway of HGF/c-MET is activated in different cancers and involved in tumorigenesis and metastasis of ovarian cancer. We present the findings of clinical studies using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, particularly in ovarian cancer. We also discuss that HGF/c-MET-targeted therapy, when combined with chemo drugs, could be an effective strategy for ovarian cancer therapeutics.
卵巢癌是女性癌症死亡的第五大主要原因，被认为是最难治疗的癌症之一。目前，正在进行研究以开发治疗卵巢癌的治疗剂。在这篇综述中，我们解释了肝细胞生长因子 (HGF)/间质上皮转化因子 (c-MET) 的特性，以及 HGF/c-MET 信号通路在不同癌症中的激活方式，以及如何参与卵巢癌的肿瘤发生和转移。我们介绍了使用针对不同癌症类型（尤其是卵巢癌）中 HGF/c-MET 信号的小分子化学物质或抗体的临床研究结果。我们还讨论了 HGF/c-MET 靶向治疗与化疗药物联合使用可能是治疗卵巢癌的有效策略。
